Deadline: 21 June 2019
USAID is soliciting Expressions of Interest (EOI) for novel and innovative approaches to malaria vaccine development that would encompass preclinical development through proof of principle clinical studies to motivate advanced development of a deployable, effective malaria vaccine.
USAID is seeking to enhance malaria vaccine investments through a collaborative design process. The goal of USAID’s Malaria Vaccine Development Program (MVDP) is to demonstrate the proof of concept of a vaccine to reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum. Target malaria vaccine end characteristics will include at least 75% efficacy and evidence of affordability. USAID intends to support efforts towards vaccines that have the potential to directly protect recipients against disease caused by P. falciparum such as vaccines that target the pre-erythrocytic (sporozoite and liver stage) and erythrocytic stages of the life cycle.
USAID is looking for EOIs that clearly include one or more of the following:
- The potential to accelerate malaria vaccine development efforts and/or enhance the effectiveness of current malaria vaccine candidates targeting pre-erythrocytic (sporozoite and liver) and erythrocytic stages through strategic research, prototype vaccine development, preclinical, and early stage clinical testing (through proof of principle efficacy studies).
- A continuation or enhancement of USAID’s current funded R&D activities or that support novel approaches that could add or replace elements of current USAID MVDP R&D investments.
USAID encourages EOIs from potential partners who have access to systems that can obtain research materials and services including expert technical support for USAID and its collaborators in support of USAID’s malaria vaccine R&D efforts.
USAID anticipates awarding one or more awards totaling up to $35,500,000 (USD) over five years.
- USAID seeks to engage with partners from the private sector, academic institutions, non-profit organizations, and other government agencies with demonstrated ability in vaccine development to identify novel and innovative approaches for malaria vaccine research and development during a co-creation Workshop.
- All organizations must be formed and legally incorporated, have the capacity to successfully execute the activities in their respective areas of expertise, and be capable of receiving and administering award funding. Sole proprietorships are not eligible for funding.
- A project can have only one Project Lead, who must be affiliated with the institution from which the EOI is being submitted. A Project Lead may only be listed on one (1) EOI to this Broad Agency Announcement. An institution may be the applicant on multiple applications, provided all EOIs have different Project Leads.
How to Apply
EOIs must be submitted electronically at the address given on the website.
For more information, please visit this link.